Metraipolis › archive › dc_9e41819feb41
Impact of the COVID-19 pandemic on routine HIV care and antiretroviral treatment outcomes in Kenya: A nationally representative analysis — Europe PMC PMID:38011132
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38011132
- DOI
- 10.1371/journal.pone.0291479
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T11:58:55.064Z
- SHA-256 of the archived text
f4494d0fe086be37f1efcc6689d60b5b17d6ae18f4baaac97403fa241c007391- Stable URL of this page
https://metraipolis.com/documento/dc_9e41819feb41
How to cite
Impact of the COVID-19 pandemic on routine HIV care and antiretroviral treatment outcomes in Kenya: A nationally representative analysis — Europe PMC PMID:38011132 — Europe PMC (en), https://europepmc.org/article/MED/38011132 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_9e41819feb41 (Metraipolis archive dc_9e41819feb41, sha256 f4494d0fe086be37f1efcc6689d60b5b17d6ae18f4baaac97403fa241c007391)
BibTeX
@misc{dc9e41819feb41,
title = {Impact of the COVID-19 pandemic on routine HIV care and antiretroviral treatment outcomes in Kenya: A nationally representative analysis — Europe PMC PMID:38011132},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38011132},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_9e41819feb41; sha256 f4494d0fe086be37f1efcc6689d60b5b17d6ae18f4baaac97403fa241c007391},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38011132. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: The COVID-19 pandemic adversely disrupted global health service delivery. We aimed to assess impact of the pandemic on same-day HIV diagnosis/ART initiation, six-months non-retention and initial virologic non-suppression (VnS) among individuals starting antiretroviral therapy (ART) in Kenya. Methods: Individual-level longitudinal service delivery data were analysed. Random sampling of individuals aged >15 years starting ART between April 2018 -March 2021 was done. Date of ART initiation was stratified into pre-COVID-19 (April 2018 -March 2019 and April 2019 -March 2020) and COVID-19 (April 2020 -March 2021) periods. Mixed effects generalised linear, survival and logistic regression models were used to determine the effect of COVID-19 pandemic on same-day HIV diagnosis/ART initiation, six-months non-retention and VnS, respectively. Results: Of 7,046 individuals sampled, 35.5%, 36.0% and 28.4% started ART during April 2018 -March 2019, April 2019 -March 2020 and April 2020 -March 2021, respectively. Compared to the pre-COVID-19 period, the COVID-19 period had higher same-day HIV diagnosis/ART initiation (adjusted risk ratio [95% CI]: 1.09 [1.04-1.13], p<0.001) and lower six-months non-retention (adjusted hazard ratio [95% CI]: 0.66 [0.58-0.74], p<0.001). Of those sampled, 3,296 (46.8%) had a viral load test done at a median 6.2 (IQR, 5.3-7.3) months after ART initiation. Compared to the pre-COVID-19 period, there was no significant difference in VnS during the COVID-19 period (adjusted odds ratio [95% CI]: 0.79 [95%% CI: 0.52-1.20], p = 0.264). Conclusions: In the short term, the COVID-19 pandemic did not have an adverse impact on HIV care and treatment outcomes in Kenya. Timely, strategic and sustained COVID-19 response may have played a critical role in mitigating adverse effects of the pandemic and point towards maturity, versatility and resilience of the HIV program in Kenya. Continued monitoring to assess long-term impact of the COVID-19 pandemic on HIV care and treatment program in Kenya is warranted. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-11-27). Identificativi: PMID 38011132 · PMCID PMC10681195 · DOI 10.1371/journal.pone.0291479. Descrittori MeSH principali: HIV Infections; Anti-HIV Agents; COVID-19. Pagina: https://europepmc.org/article/MED/38011132 — https://doi.org/10.1371/journal.pone.0291479. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:29:04.309Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.